ClinicalTrials.gg

Program

vonoprazan

Also written as “TAK-438”, “Vonoprazan” and “Vonoprazan (Reference)”.

Its studies are mostly in Esophagitis · Stomach Ulcer · Gastroesophageal Reflux · Heartburn · Duodenal Ulcer, led by 5 companies.

Furthest: phase 4, since Feb 8, 201648 company-led studies, 2 open or runningNext primary completion: Oct 20, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takeda310 open or runningphase 4since Feb 8, 2016Sep 16, 2011none ahead
Phathom Pharmaceuticals142 open or runningphase 3since Oct 10, 2019Oct 10, 2019Oct 20, 2027phase 3 · NCT07752407
Genuine Research Center, Egypt10 open or runningphase 1since Nov 14, 2021Nov 14, 2021none ahead
Hanlim Pharm.10 open or runningphase 1since Oct 14, 2024Oct 14, 2024none ahead
Humanis Saglık Anonim Sirketi10 open or runningphase 1since Dec 9, 2025Dec 9, 2025none ahead

Also a collaborator on its studies: richmond-pharmacology-limited.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 34 studies since Sep 16, 2011.

  1. Jan 19, 2021Phase 1 study in Healthy ParticipantsPhathom Pharmaceuticals · NCT04729101 · 44 enrolled · United States
  2. Feb 12, 2021Phase 1 study in Helicobacter PyloriTakeda · NCT04753437 · 44 enrolled · China
  3. Mar 11, 2021Phase 2 study in HeartburnPhathom Pharmaceuticals · NCT04799158 · 458 enrolled · United States
  4. Nov 14, 2021Genuine Research Center, Egypt's first study: phase 1 study in HealthyNew to Genuine Research Center, EgyptGenuine Research Center, Egypt · NCT05135793 · 29 enrolled · Egypt
  5. Jan 4, 2022Phase 3 study in HeartburnPhathom Pharmaceuticals · NCT05195528 · 776 enrolled · United States
  6. Apr 18, 2022Phase 1 study in Gastroesophageal RefluxPhathom Pharmaceuticals · NCT05343364 · 24 enrolled · United States
  7. May 4, 2022Phase 1 study in Gastroesophageal RefluxPhathom Pharmaceuticals · NCT05366738 · 27 enrolled · United States
  8. Oct 24, 2023Phase 1 study in Gastroesophageal RefluxPhathom Pharmaceuticals · NCT06106022 · 22 enrolled · United States
  9. Apr 25, 2024Phase 1 study in HeartburnPhathom Pharmaceuticals · NCT06391177 · 15 enrolled · United States
  10. Oct 14, 2024Hanlim Pharm.'s first study: phase 1 study in Stomach UlcerNew to Hanlim Pharm.Hanlim Pharm. · NCT06642987 · 30 enrolled · Korea, Republic of
  11. Feb 14, 2025Phase 1 study in Healthy VolunteersPhathom Pharmaceuticals · NCT06831344 · 25 enrolled · United States
  12. Feb 24, 2025Phase 2 study in Eosinophilic EsophagitisPhathom Pharmaceuticals · NCT06851559 · 95 enrolled · United States
  13. Dec 9, 2025Humanis Saglık Anonim Sirketi's first study: phase 1 study in Erosive GastritisNew to Humanis Saglık Anonim SirketiHumanis Saglık Anonim Sirketi · NCT07278349 · 28 enrolled · Jordan
  14. Aug 3, 2026Phase 3 study in Gastroesophageal RefluxPhathom Pharmaceuticals · NCT07752407 · 500 planned · United States

Ahead

  1. Oct 20, 2027Primary completion: phase 3 study in Gastroesophageal RefluxPhathom Pharmaceuticals · NCT07752407

TargetBeta

ATP4A →ATP4B →read by rule
“Potassium-transporting ATPase inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
EsomeprazoleruleAstraZenecaphase 4129
RabeprazoleruleEisaiphase 466
OmeprazoleruleAstraZenecaphase 456
tegoprazanruleHK inno.Nphase 448
fexuprazanruleDaewoong Pharmaceuticalphase 429

Studies

All 48 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07752407Gastroesophageal Reflux · United States3RecruitingPhathom PharmaceuticalsOct 20, 2027500
NCT07278349Erosive Gastritis · Jordan1CompletedHumanis Saglık Anonim SirketiOct 4, 202528
NCT06851559Eosinophilic Esophagitis · United States2Active, not recruitingPhathom PharmaceuticalsSep 11, 202695
NCT06831344Healthy Volunteers · United States1CompletedPhathom PharmaceuticalsApr 5, 202525
NCT06642987Stomach Ulcer · Korea, Republic of1CompletedHanlim Pharm.Nov 3, 202330
NCT06391177Heartburn · United States1CompletedPhathom PharmaceuticalsSep 13, 202415
NCT06106022Gastroesophageal Reflux · United States1CompletedPhathom PharmaceuticalsApr 16, 202422
NCT05366738Gastroesophageal Reflux · United States1CompletedPhathom PharmaceuticalsJul 1, 202227
NCT05343364Gastroesophageal Reflux · United States1CompletedPhathom PharmaceuticalsMay 30, 202324
NCT05195528Heartburn · United States3CompletedPhathom PharmaceuticalsNov 21, 2022776
NCT05135793Healthy · Egypt1CompletedGenuine Research Center, EgyptFeb 2, 202129
NCT04799158Heartburn · United States2CompletedPhathom PharmaceuticalsDec 16, 2021458
NCT04753437Helicobacter Pylori · China1CompletedTakedaSep 27, 202144
NCT04729101Healthy Participants · United States1CompletedPhathom PharmaceuticalsJun 12, 202144
NCT04558216Healthy Participants · United States1WithdrawnPhathom PharmaceuticalsFeb 7, 20210
NCT04545944Healthy Volunteers · United States1CompletedPhathom PharmaceuticalsNov 13, 202020
NCT04198363Helicobacter Pylori · China3CompletedTakedaNov 1, 2021510
NCT04167670Helicobacter Pylori Infection · United States, Bulgaria, Czechia and more3CompletedPhathom PharmaceuticalsMar 10, 20211,046
NCT04124926Erosive Esophagitis · United States, Bulgaria, Czechia and more3CompletedPhathom PharmaceuticalsJul 29, 20211,027
NCT03808493Japanese Healthy Adult Male · Japan1CompletedTakedaMar 12, 201948
NCT03116841Esophagitis, Peptic · Japan4CompletedTakedaDec 20, 20173
NCT03085836Healthy Participants · China1CompletedTakedaAug 17, 201733
NCT03050359Duodenal Ulcer · China, Korea, Republic of, Philippines and more3CompletedTakedaMar 19, 2019533
NCT03050307Stomach Ulcer · China, Korea, Republic of, Philippines and more3CompletedTakedaFeb 19, 2020234
NCT02954848Non-erosive Gastroesophageal Reflux Disease · Japan3CompletedTakedaFeb 25, 2018484
NCT02892409Helicobacter Pylori · Korea, Republic of1CompletedTakedaApr 17, 201730
NCT02774902Healthy Volunteers1CompletedTakedaSep 201016
NCT02679508Esophagitis · Japan4CompletedTakedaMar 5, 2022208
NCT02388737Erosive Esophagitis · China, Korea, Republic of, Malaysia and more3CompletedTakedaDec 24, 2018703
NCT02388724Erosive Esophagitis · China, Korea, Republic of, Malaysia and more3CompletedTakedaJul 27, 2017481
NCT02141711Gastroesophageal Reflux · United Kingdom1CompletedTakedaFeb 200948
NCT02141698Dose Finding Study1CompletedTakedaFeb 200873
NCT02123953Dose Finding Study1CompletedTakedaMar 200960
NCT02123927Ascending Single Dose Study1CompletedTakedaDec 2007108
NCT01630746Erosive Esophagitis · Japan3CompletedTakedaSep 201319
NCT01568398Stomach Ulcer · Japan3CompletedTakedaAug 201327
NCT01568385Stomach Ulcer · Japan3CompletedTakedaSep 201330
NCT01505127H. Pylori Infection · Japan3CompletedTakedaJun 2013650
NCT01474369Non-erosive Gastroesophageal Reflux Disease · Japan3CompletedTakedaFeb 2013827
NCT01459367Erosive Esophagitis · Japan3CompletedTakedaMar 2013607
NCT01456260Stomach Ulcer · Japan3CompletedTakeda406
NCT01456247Stomach Ulcer · Japan3CompletedTakedaOct 2013439
NCT01452776Erosive Esophagitis · Japan3CompletedTakedaJul 2013305
NCT01452763Stomach Ulcer · Japan3CompletedTakedaApr 2013621
NCT01452750Stomach Ulcer · Japan3CompletedTakedaJun 2013642
NCT01452724Duodenal Ulcer · Japan3CompletedTakedaFeb 2013372
NCT01452711Stomach Ulcer · Japan3CompletedTakedaDec 2012482
NCT01452698Erosive Esophagitis · Japan3CompletedTakedaAug 2012409

How it is read

Names in the registry

  • “TAK-438”, 32 entries
  • “Vonoprazan”, 20 entries
  • “Vonoprazan (Reference)”, 1 entry
  • “Vonoprazan Tablets”, 1 entry
  • “VOQUEZNA® Tablets”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.